Celerion is expanding its presence in Singapore and has appointed Dr. Chew Lan Chong, MBBS, MRCS, MSc, as executive director of Medical Research. Dr. Chong has 10 years of operational experience leading clinical pharmacology units and has conducted more than 130 early clinical studies at organizations including Pfizer and Lilly in Singapore.  
 
Dr. Chong will lead Celerion’s business operations in Singapore, provide medical and scientific expertise and collaborate with partner early clinical research units to conduct complex early clinical pharmacology studies in accordance with global standards.
 
Celerion also recently expanded into South Korea, opening clinical operations at Seoul National University Hospital (SNUH) Clinical Trial Center, and entered a collaboration with the Korean Drug Development Fund (KDDF).
 
These expansions will provide access to Asian patients and healthy participants for early clinical research studies, including oncology, hepatitis B, cardiovascular, diabetes, arthritis, osteoporosis, pain, psychiatric conditions, Alzheimer’s disease, Parkinson’s disease, asthma and COPD. In addition, Celerion’s partners will provide pharmacogenetics and ethnic bridging studies in Asian populations.
 
“We are delighted to continue to build a strong footprint in Asia with our new office in Singapore, headed up by Chew Lan,” said Frederick Pritchard Ph.D., vice president of Global Drug Development at Celerion. “The continued expansion in Asia demonstrates Celerion’s commitment to providing clients innovative solutions to conduct patient studies. Dr. Chong’s academic qualifications and practical experience make her the perfect choice to head up our operations in Singapore conducting the types of innovative and challenging studies involved in translational and experimental medicine.”